$2.13
+0.14 (+7.04%)
Open$1.99
Previous Close$1.99
Day High$2.15
Day Low$1.99
52W High$2.38
52W Low$1.13
Volume—
Avg Volume214.9K
Market Cap196.20M
P/E Ratio5.55
EPS$0.36
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+2,081.2% upside
Current
$2.13
$2.13
Target
$46.46
$46.46
$33.82
$46.46 avg
$60.35
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 74.59M | 14.58M | 13.34M |
| Net Income | 36.23M | 2.88M | 3.22M |
| Profit Margin | 48.6% | 19.8% | 24.2% |
| EBITDA | 33.08M | 4.55M | 4.43M |
| Free Cash Flow | — | 4.06M | 3.77M |
| Rev Growth | +113.3% | -8.4% | -7.1% |
| Debt/Equity | — | 0.65 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |